Bromocriptine, Sex Steroid Metabolism, and Menstrual Patterns in the Polycystic Ovary Syndrome
Authors: Jonathan J. Pehrson, Judith Vaitukaitis, Christopher Longcope
Journal: Annals of Internal Medicine (1986)

Editorials1 July 1986Bromocriptine, Sex Steroid Metabolism, and Menstrual Patterns in the Polycystic Ovary SyndromeJONATHAN J. PEHRSON, M.D., JUDITH VAITUKAITIS, M.D., CHRISTOPHER LONGCOPE, M.D.JONATHAN J. PEHRSON, M.D.Search for more papers by this author, JUDITH VAITUKAITIS, M.D.Search for more papers by this author, CHRISTOPHER LONGCOPE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-1-129 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPolycystic ovary syndrome is one of the commonest endocrinologic disorders of reproduction, and the disorder probably reflects a primary hypothalamic defect resulting in altered patterns of gonadotropin and prolactin secretion (1). Women usually present during their early reproductive years with various degrees and combinations of menstrual dysfunction and with signs of androgen excess and polycystic ovaries. The wide spectrum of clinical and biochemical abnormalities is presumably the result of differences in severity and duration of the syndrome, sex steroid metabolism, and end-organ sensitivities.The characteristic polycystic ovary contains numerous follicular cysts in varied stages of development and atresia, surrounded by...References1. JAFFEEVAITUKAITIS WJ. Polycystic ovary syndrome. In: VAITUKAITIS JL, ed. Clinical Reproductive Neuroendocrinology New York: Elsevier Biomedical; 1982:207-30. Google Scholar2. GOLDZIEHER J. Polycystic ovarian disease. Fertil Steril. 1981;35:371-94. CrossrefMedlineGoogle Scholar3. ERIKSONHSEUHQUIGLEYREBARYEN GAMRS. Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries. J Clin Endocrinol Metab. 1979;49:514-9. CrossrefMedlineGoogle Scholar4. PARKERODELL LW. Control of adrenal androgen secretion. Endoc Rev. 1980;1:392-410. CrossrefMedlineGoogle Scholar5. QUIGLEYRAKOFFYEN MJS. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab. 1981;52:231-4. CrossrefMedlineGoogle Scholar6. SPRUCEKENDALL-TAYLORDUNLOP BPW. The effect of bromocriptine in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1984;20:481-8. CrossrefMedlineGoogle Scholar7. ZUMOFFFREEMANNCOUPEYSAENGERMARKOWITZKREANIN BRSPMJ. A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. N Engl J Med. 1983;309:1206-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JONATHAN J. PEHRSON, M.D.; JUDITH VAITUKAITIS, M.D.; CHRISTOPHER LONGCOPE, M.D.Affiliations: University of Massachusetts School of Medicine Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySelected Aspects of Polycystic Ovarian DiseasePathogenesis and Treatment of Polycystic Ovary SyndromePolycystic ovaries and polycystic ovary syndrome 1 July 1986Volume 105, Issue 1Page: 129-130KeywordsAndrogensEndocrinologyGonadotropinsOvariesPolycystic ovary syndromeProlactinResearch grants ePublished: 1 December 2008 Issue Published: 1 July 1986 PDF downloadLoading ...